Polymer(Korea) (폴리머)

The Polymer Society of Korea (한국고분자학회)
권호 표지

Effect of the Viscosity of (Hydroxypropyl)methyl Cellulose on Dissolution Rate of Alfuzosin-HCl Granule Tablet

HPMC의 점도에 따른 염산 알푸조신 과립정제의 용출률 조절

  • Kim, Won (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University) ;
  • Song, Byung-Joo (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University) ;
  • Kim, Dae-Sung (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University) ;
  • Kim, Su-Jin (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University) ;
  • Lee, Seon-Kyoung (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University) ;
  • Kim, Hye-Lin (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University) ;
  • Lee, Dong-Won (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University) ;
  • Khang, Gil-Son (Department of BIN Fusion Technology & Department of Polymer Nano Science & Technology, Chonbuk National University)
  • 김원 (전북대학교 BIN 융합공학과, 고분자나노공학과) ;
  • 송병주 (전북대학교 BIN 융합공학과, 고분자나노공학과) ;
  • 김대성 (전북대학교 BIN 융합공학과, 고분자나노공학과) ;
  • 김수진 (전북대학교 BIN 융합공학과, 고분자나노공학과) ;
  • 이선경 (전북대학교 BIN 융합공학과, 고분자나노공학과) ;
  • 김혜린 (전북대학교 BIN 융합공학과, 고분자나노공학과) ;
  • 이동원 (전북대학교 BIN 융합공학과, 고분자나노공학과) ;
  • 강길선 (전북대학교 BIN 융합공학과, 고분자나노공학과)
  • Received : 2010.01.08
  • Accepted : 2010.02.10
  • Published : 2010.05.25
Download PDF
⟨ Previous Next ⟩

Abstract

The primary objective of this work is to find the optimal condition for the granule tablet formulation of alfuzosin-HCl that aims to achieve a sustained drug release. (Hydroxypropyl)methyl cellulose (HPMC) is one of the most widely used polymer as a drug formulation and therefore has been utilized in this study as an excipient. Alfuzosin-HCl granule tablet was developed using the various viscosities of HPMC and the effects of viscosity on drug release was investigated. Fourier transform-infrared (FTIR) and X-ray diffraction (XRD) were employed to investigate the chemical structure and crystallization of alfuzosin-HCl in the formulation. We prepared the granule tablet by a direct compression method and studied the release profile in the stimulated intestinal fluid (pH 6.8). As the viscosity of HPMC increased the release of alfuzosin-HCl decreased, demonstrating that controlled release of alfuzosin-HCl can be achieved by varying the viscosity of HPMC.

본 연구는 염산 알푸조신의 서방화를 위한 과립제의 최적 구성을 찾기 위해 수행되었으며, 이에 따라 고분자의 점도에 따른 염산 알푸조신 과립정제를 제조하였다. 사용된 고분자는 경구를 통한 약물전달 시스템 설계에 가장 널리 사용되는 하이드록시프로필메틸셀룰로오스(HPMC)이며, HPMC의 팽윤성은 가장 중요한 특성으로 약물의 방출에 큰 영향을 미친다. 염산 알푸조신 과립정제의 구조변화를 확인하기 위하여 적외선분광법(FTIR)을 분석하였으며, 결정학적 특성을 알아보기 위해 X선 회절분석법(XRD)을 이용하여 분석하였다. 과립정제를 제조하여 인공장액에서의 방출거동을 알아보았으며, 본 연구를 통해 첨가제로 사용된 HPMC의 점도에 따라 모델약물인 염산 알푸조신의 방출거동을 조절할 수 있었다.

Keywords

References

  1. D. B. Patel and N. J. Patel, Int. J. Chem. Tech. Res., 1, 985 (2009).
  2. K. T. McVary, J. Urol., 175, 35 (2006). https://doi.org/10.1016/S0022-5347(05)00032-7
  3. S. J. Berry, D. S. Coffey, P. C. Walsh, and L. L. Ewing, J. Urol., 132, 474 (1984). https://doi.org/10.1016/S0022-5347(17)49698-4
  4. W. M. Garraway, G. N. Collins, and R. J. Lee, Lancet, 338, 469 (1991). https://doi.org/10.1016/0140-6736(91)90543-X
  5. G. P. Hoke, Am. J. Med., 121, S3 (2003).
  6. S. H. Lee, J. Korean Acad. Fam. Med., 28, 193 (2007).
  7. H. S. Chang and C. H. Park, J. Korean Continence Society, 7, 25 (2003). https://doi.org/10.5213/jkcs.2003.7.1.25
  8. C. Franklin and M. D. Lowe, Clin. Ther., 26, 1701 (2004). https://doi.org/10.1016/j.clinthera.2004.11.006
  9. M. Miner, T. Matt, and Rosenberg, Clin. Ther., 28, 13 (2006). https://doi.org/10.1016/j.clinthera.2006.01.004
  10. J. Y. Lee, N. K. Choi, S. Y. Jung, Y. J. Kim, J. M. Seong, S. J. Oh, and B. J. Park, J. Prev. Med. Public Health, 42, 165 (2009). https://doi.org/10.3961/jpmph.2009.42.3.165
  11. C. R. Chapple, Rev. Urol., 7, 22 (2005).
  12. W. J. G. Hellstrom and S. C. Sikka, J. Urol., 176, 1529 (2006). https://doi.org/10.1016/j.juro.2006.06.004
  13. M. C. Blouin, J. Cataract Refract. Surg., 33,1227 (2007). https://doi.org/10.1016/j.jcrs.2007.03.032
  14. N. A. Gomes, A. Pudage, S. S. Joshi, V. V. Vaidya, S. A. Parekh, and A. V. Tamhankar, Chromatographia, 69, 9 (2009). https://doi.org/10.1365/s10337-008-0821-1
  15. H. N. Mistri, A. G. Jangid, A. Pudage, D. M. Rathod, and P. S. Shrivastav, J. Chromatogr. B, 876, 236 (2008). https://doi.org/10.1016/j.jchromb.2008.10.050
  16. A. E. Lacerda, Y. A. Kuryshev, Y. Chen, M. Renganathan, H. Eng, S. J. Danthi, J. W. Kramer, T. Yang, and A. M. Brown, J. Pharmacol. Exp. Ther., 324, 427 (2008).
  17. S. Pattnaik, K. Swain, and S. Mallick, Lat. Am. J. Pharm., 28, 62 (2009).
  18. Q. Liu and R. Fassihi, Int. J. Pharm., 348, 27 (2008), https://doi.org/10.1016/j.ijpharm.2007.07.009
  19. B. H. Chung, Korean J. Urol., 48, 233 (2007). https://doi.org/10.4111/kju.2007.48.3.233
  20. A. Jardin, H. Bensadoun, M. C. Delauche-Cavallier, A. Stalla-Bourdillon, and P. Attali, Br. J. Urol., 74, 579 (1994). https://doi.org/10.1111/j.1464-410X.1994.tb09187.x
  21. N. Mottet, F. Bressolle, V. Delmas, M. Robert, and P. Costa, Eur. Urol., 44, 101 (2003). https://doi.org/10.1016/S0302-2838(03)00154-4
  22. S. C. Jeong, S. K. Chon, Y. H. Jo, M. S. Kim, B. Lee, G. Khang, and H. B. Lee, Polymer(Korea), 29, 288 (2005).
  23. J. Siepmann and N. A. Peppas, Adv. Drug Deliv. Rev., 48, 139 (2001). https://doi.org/10.1016/S0169-409X(01)00112-0
  24. P. Colombo, Adv. Drug Deliv. Rev., 11, 37 (1993). https://doi.org/10.1016/0169-409X(93)90026-Z
  25. J. Y. Youn, S. W. Park, S. Y. Lee, M. S. Kim, B. Lee, G. Khang, and H. B. Lee, Polymer(Korea), 32, 322 (2008).
  26. J. L. Ford, M. H. Rubinstein, and J. E. Hoagen, Int. J. Pharm., 24, 327 (1985). https://doi.org/10.1016/0378-5173(85)90031-6
  27. K. Mitchell, J. L. Ford, M. H. Rubinstein, D. J. Armstrong, P. N. C. Elliot, J. E. Hoagen, and C. Rostron, Int. J. Pharm., 156, 49 (1997). https://doi.org/10.1016/S0378-5173(97)00180-4
  28. H. Kurahashi, H. Kami, and H. Sanada, Chem. Pharm. Bull., 44, 829 (1996). https://doi.org/10.1248/cpb.44.829
  29. L. S. Marks, C. G. Roehrhorn, and M. Gittelman, Adult Urol., 62, 888 (2003).
  30. J. H. Park, S. H. Kim, J. M. Oh, S. I. Ahn, Y. T. Kim, S. H. Jung, J. H. Choi, D. Lee, I. Yoo, J. M. Rhee, and G. Khang, Tissue Eng. Regen. Med., 6, 995 (2009).
  31. B. J. Lee, et aI., Galenical Pharmacy, Hanrimwon, Seoul, 2004.
  32. J. H. Im, Y. Lee, and K. M. Huh, Polymer(Korea), 32, 143 (2008).
  33. J. S. Park, J. S. Oh, J. M. Oh, Y. T. Kim, J. H. Lee, J. H. Mo, H. B. Lee, and G. Khang, Polymer(Korea), 32, 193 (2008).
  34. J. Y. Youn, J. Ku, S. Y. Lee, B. S. Kim, M. S. Kim, B. Lee, G. Khang, and H. B. Lee, Polymer(Korea), 31, 329 (2007).
  35. D. S. Kim, K. Y. Seong, W. Kim, H. K. Hong, S. I. Ahn, J. H. Park, J. M. Oh, Y. T. Kim, E. Y. Lee, D. Lee, J. M. Rhee, and G. Khang, Tissue Eng. Regen. Med., 6, 903 (2009).
  36. S. Virtanen, H. Salokangsa, and J. Yliruusi, Eur. J. Pharm. Sci., 34, S27 (2008).
  37. P. Mura, M. T. Fauucci, A. Manderioli, G. Bramanti, and L. Ceccarelli, J. Pharmaceut. Biomed., 18, 151 (1998). https://doi.org/10.1016/S0731-7085(98)00171-X
  38. A. C. Williams, P. Timmins, M. Lu, and R. T. Forbes, Eur. J. Pharm. Sci., 26, 288 (2005). https://doi.org/10.1016/j.ejps.2005.06.006
  39. J. H. Park, J. Ku, S. I. Ahn, J. H. Lee, Y. T. Kim, D. S. Kim, W. Kim, J. M. Rhee, and G. Khang, Tissue Eng. Regen. Med., 5, 729 (2008).